antibody

Goat anti-ZNF9/CNBP Antibody

MBS421421

0.1 mg

300 USD

polyclonal

goat

nonconjugated

human, mouse, rat, dog

western blot, enzyme immunoassay

Antibody

Goat anti-ZNF9/CNBP Antibody

ZNF9/CNBP

ZNF9; CNBP; zinc finger protein 9 (a cellular retroviral nucleic acid binding protein); HGNC: 13164; CNBP1; DM2; PROMM; RNF163; Proximal myotonic myopathy nucleic acid binding protein; zinc finger protein 273; zinc finger protein 9; ZNF9 antibody; CNBP antibody; zinc finger protein 9 (a cellular retroviral nucleic acid binding protein) antibody; HGNC: 13164 antibody; CNBP1 antibody; DM2 antibody; PROMM antibody; RNF163 antibody; Proximal myotonic myopathy nucleic acid binding protein antibody; zinc finger protein 273 antibody; zinc finger protein 9 antibody; ZNF9 / CNBP

cellular nucleic acid-binding protein isoform 3; Cellular nucleic acid-binding protein; cellular nucleic acid-binding protein; CCHC-type zinc finger nucleic acid binding protein; Zinc finger protein 9

CNBP

CNBP

CNBP; CNBP; DM2; ZNF9; CNBP1; PROMM; RNF163; ZCCHC22; RNF163; ZNF9; CNBP

CNBP_HUMAN

Polyclonal

Goat

Tested: Human; Expected from sequence similarity: Human, Mouse, Rat, Dog

177

GESGHLARECTIE

Purified from goat serum by ammonium sulphate precipitation followed by antigen affinity chromatography using the immunizing peptide

Supplied at 0.5 mg/ml in Tris saline, 0. 02% sodium azide, pH7.3 with 0.5% bovine serum albumin.

100ug specific antibody in 200ul

Aliquot and store at -20 degree C. Minimize freezing and thawing.

Peptide ELISA (EIA), Western Blot (WB)

Peptide ELISA: Antibody detection limit dilution 1: 8000. Western Blot: Approx 19kDa band observed in Human Skeletal Muscle lysates (calculated MW of 19.5kDa according to NP_003409.1). Recommended concentration: 1-3ug/ml.

Immunogen: Peptide with sequence GESGHLARECTIE, from the C Terminus of the protein sequence according to NP_003409.1. Epitope: C Terminus

4827071

NP_003409.1

NM_003418.4

18,871 Da

This gene encodes a nucleic-acid binding protein with seven zinc-finger domains. The protein has a preference for binding single stranded DNA and RNA. The protein functions in cap-independent translation of ornithine decarboxylase mRNA, and may also function in sterol-mediated transcriptional regulation. A CCTG expansion in the first intron of this gene results in myotonic dystrophy type 2. Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]

ZNF9: Single stranded DNA-binding protein, with specificity to the sterol regulatory element (SRE). Involved in sterol-mediated repression. Defects in CNBP are the cause of dystrophia myotonica type 2 (DM2); also known as proximal myotonic myopathy (PROMM). A multisystem disease characterized by the association of proximal muscle weakness with myotonia, cardiac manifestations and cataract. Additional features can include hyperhidrosis, testicular atrophy, insulin resistance and diabetes and central nervous system anomalies in rare cases. The causative mutation is a CCTG expansion (mean approximately 5000 repeats) located in intron 1 of the CNBP gene. 5 isoforms of the human protein are produced by alternative splicing. Protein type: RNA-binding; Transcription factor; DNA-binding. Chromosomal Location of Human Ortholog: 3q21. Cellular Component: cytosol; endoplasmic reticulum; nucleus. Molecular Function: protein binding; single-stranded DNA binding; single-stranded RNA binding; transcription factor activity; zinc ion binding. Biological Process: cholesterol biosynthetic process; positive regulation of cell proliferation; positive regulation of transcription from RNA polymerase II promoter; positive regulation of transcription, DNA-dependent; regulation of transcription, DNA-dependent; transcription, DNA-dependent. Disease: Myotonic Dystrophy 2

0.1 mg

300 USD